Alzheimer’s-focused researchers are using the Alamar platform to profile 21,000 plasma samples as part of a consortium effort aimed at improving detection of Alzheimer’s and related neurological proteinopathies. The initiative is building a large-scale plasma proteomic dataset to address gaps in biomarker specificity and improve candidate selection for earlier intervention trials. The effort leverages plasma protein profiling as a potential bridge between high-sensitivity blood tests and disease-stage discrimination needs. For companies working on dementia diagnostics, large proteomic datasets also provide training ground for assay refinement and risk stratification models. As dementia diagnosis expands beyond amyloid-only approaches, the proteomics push highlights the field’s continued push toward multi-protein or composite biomarker strategies.